108 related articles for article (PubMed ID: 21574148)
1. [Neuroendocrine target therapies for prostate cancer].
Sciarra A; Innocenzi M; Ravaziol M; Minisola F; Alfarone A; Cattarino S; Monti G; Gentile V; Di Silverio F
Urologia; 2011; 78(2):137-41. PubMed ID: 21574148
[TBL] [Abstract][Full Text] [Related]
2. New perspective in the management of neuroendocrine differentiation in prostate adenocarcinoma.
Sciarra A; Cardi A; Dattilo C; Mariotti G; Di Monaco F; Di Silverio F
Int J Clin Pract; 2006 Apr; 60(4):462-70. PubMed ID: 16620361
[TBL] [Abstract][Full Text] [Related]
3. Somatostatin analogues and estrogens in the treatment of androgen ablation refractory prostate adenocarcinoma.
Sciarra A; Bosman C; Monti G; Gentile V; Autran Gomez AM; Ciccariello M; Pastore A; Salvatori G; Fattore F; Di Silverio F
J Urol; 2004 Nov; 172(5 Pt 1):1775-83. PubMed ID: 15540720
[TBL] [Abstract][Full Text] [Related]
4. Combination therapy of ethinylestradiol and somatostatin analogue reintroduces objective clinical responses and decreases chromogranin a in patients with androgen ablation refractory prostate cancer.
Di Silverio F; Sciarra A
J Urol; 2003 Nov; 170(5):1812-6. PubMed ID: 14532782
[TBL] [Abstract][Full Text] [Related]
5. Long-term response to combination therapy with estramustine and somatostatin analogue in a patient with androgen ablation-refractory prostate cancer.
Cerulli C; Sciarra A; Salvatori G; Di Silverio F
Urology; 2004 Dec; 64(6):1231.e1-3. PubMed ID: 15596212
[TBL] [Abstract][Full Text] [Related]
6. Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors--the International Lanreotide and Interferon Alfa Study Group.
Faiss S; Pape UF; Böhmig M; Dörffel Y; Mansmann U; Golder W; Riecken EO; Wiedenmann B;
J Clin Oncol; 2003 Jul; 21(14):2689-96. PubMed ID: 12860945
[TBL] [Abstract][Full Text] [Related]
7. Ultra-high-dose lanreotide treatment in patients with metastatic neuroendocrine gastroenteropancreatic tumors.
Faiss S; Räth U; Mansmann U; Caird D; Clemens N; Riecken EO; Wiedenmann B
Digestion; 1999; 60(5):469-76. PubMed ID: 10473972
[TBL] [Abstract][Full Text] [Related]
8. Effects of the somatostatin analog lanreotide on the circulating levels of chromogranin-A, prostate-specific antigen, and insulin-like growth factor-1 in advanced prostate cancer patients.
Berruti A; Dogliotti L; Mosca A; Tarabuzzi R; Torta M; Mari M; Gorzegno G; Fontana D; Angeli A
Prostate; 2001 May; 47(3):205-11. PubMed ID: 11351350
[TBL] [Abstract][Full Text] [Related]
9. Is lanreotide and/or interferon alfa an adequate therapy for neuroendocrine tumors?
Völter V; Peschel C
J Clin Oncol; 2004 Feb; 22(3):573; author reply 574-5. PubMed ID: 14752089
[No Abstract] [Full Text] [Related]
10. Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors.
Fazio N; Oberg K
J Clin Oncol; 2004 Feb; 22(3):573-4; author reply 574-5. PubMed ID: 14752088
[No Abstract] [Full Text] [Related]
11. A combination therapy of dexamethasone and somatostatin analog reintroduces objective clinical responses to LHRH analog in androgen ablation-refractory prostate cancer patients.
Koutsilieris M; Mitsiades C; Dimopoulos T; Ioannidis A; Ntounis A; Lambou T
J Clin Endocrinol Metab; 2001 Dec; 86(12):5729-36. PubMed ID: 11739429
[TBL] [Abstract][Full Text] [Related]
12. Pancreatic neuroendocrine neoplasms.
Hörsch D; Bert T; Schrader J; Hommann M; Kaemmerer D; Petrovitch A; Zaknun J; Baum RP
Minerva Gastroenterol Dietol; 2012 Dec; 58(4):401-26. PubMed ID: 23207615
[TBL] [Abstract][Full Text] [Related]
13. Neuroendocrine differentiation in castration-resistant prostate cancer: a systematic diagnostic attempt.
Matei DV; Renne G; Pimentel M; Sandri MT; Zorzino L; Botteri E; De Cicco C; Musi G; Brescia A; Mazzoleni F; Tringali V; Detti S; de Cobelli O
Clin Genitourin Cancer; 2012 Sep; 10(3):164-73. PubMed ID: 22401754
[TBL] [Abstract][Full Text] [Related]
14. [Current diagnostic procedure on neuroendocrine differentiation of prostate cancer].
Sciarra A; Innocenzi M; Ravaziol M; Minisola F; Alfarone A; Cattarino S; Panebianco V; Buonocore V; Gentile V; Di Silverio F
Urologia; 2011; 78(2):132-6. PubMed ID: 21574146
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of the efficacy and safety of lanreotide in combination with targeted therapies in patients with neuroendocrine tumours in clinical practice: a retrospective cross-sectional analysis.
Capdevila J; Sevilla I; Alonso V; Antón Aparicio L; Jiménez Fonseca P; Grande E; Reina JJ; Manzano JL; Alonso Lájara JD; Barriuso J; Castellano D; Medina J; López C; Segura Á; Carrera S; Crespo G; Fuster J; Munarriz J; García Alfonso P
BMC Cancer; 2015 Jul; 15():495. PubMed ID: 26138480
[TBL] [Abstract][Full Text] [Related]
16. Establishing the Quantitative Relationship Between Lanreotide Autogel®, Chromogranin A, and Progression-Free Survival in Patients with Nonfunctioning Gastroenteropancreatic Neuroendocrine Tumors.
Buil-Bruna N; Dehez M; Manon A; Nguyen TX; Trocóniz IF
AAPS J; 2016 May; 18(3):703-12. PubMed ID: 26908127
[TBL] [Abstract][Full Text] [Related]
17. Circulating Transcript Analysis (NETest) in GEP-NETs Treated With Somatostatin Analogs Defines Therapy.
Ćwikła JB; Bodei L; Kolasinska-Ćwikła A; Sankowski A; Modlin IM; Kidd M
J Clin Endocrinol Metab; 2015 Nov; 100(11):E1437-45. PubMed ID: 26348352
[TBL] [Abstract][Full Text] [Related]
18. The combination of docetaxel and the somatostatin analogue lanreotide on androgen-independent docetaxel-resistant prostate cancer: experimental data.
Lo Nigro C; Maffi M; Fischel JL; Formento P; Milano G; Merlano M
BJU Int; 2008 Aug; 102(5):622-7. PubMed ID: 18494832
[TBL] [Abstract][Full Text] [Related]
19. [Role of neuroendocrine cells in prostate cancer progression].
Sciarra A; Innocenzi M; Ravaziol M; Minisola F; Alfarone A; Cattarino S; Panebianco V; Buonocore V; Gentile V; Di Silverio F
Urologia; 2011; 78(2):126-31. PubMed ID: 21574145
[TBL] [Abstract][Full Text] [Related]
20. Lanreotide delays progression of neuroendocrine tumours.
Gilbert JA
Lancet Oncol; 2014 Sep; 15(10):e418. PubMed ID: 25328940
[No Abstract] [Full Text] [Related]
[Next] [New Search]